CN101384602A - 用于治疗心血管疾病的新的环取代的呋喃并嘧啶衍生物及其用途 - Google Patents

用于治疗心血管疾病的新的环取代的呋喃并嘧啶衍生物及其用途 Download PDF

Info

Publication number
CN101384602A
CN101384602A CNA200680053205XA CN200680053205A CN101384602A CN 101384602 A CN101384602 A CN 101384602A CN A200680053205X A CNA200680053205X A CN A200680053205XA CN 200680053205 A CN200680053205 A CN 200680053205A CN 101384602 A CN101384602 A CN 101384602A
Authority
CN
China
Prior art keywords
group
compound
formula
representative
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200680053205XA
Other languages
English (en)
Chinese (zh)
Inventor
T·拉姆佩
E·-M·贝克尔
R·卡斯特
H·贝克
M·杰斯克
J·舒马彻
F·斯托尔
M·克莱茵
M·阿克巴巴
A·诺尔
J·-P·斯塔什
L·巴法克
A·希利什
G·卡里格
M·梅宁豪斯
K·-H·斯莱默
R·肖赫-卢普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CN101384602A publication Critical patent/CN101384602A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CNA200680053205XA 2005-12-21 2006-12-08 用于治疗心血管疾病的新的环取代的呋喃并嘧啶衍生物及其用途 Pending CN101384602A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005061171.0 2005-12-21
DE102005061171A DE102005061171A1 (de) 2005-12-21 2005-12-21 Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
CN101384602A true CN101384602A (zh) 2009-03-11

Family

ID=37758644

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200680053205XA Pending CN101384602A (zh) 2005-12-21 2006-12-08 用于治疗心血管疾病的新的环取代的呋喃并嘧啶衍生物及其用途

Country Status (14)

Country Link
US (1) US8324222B2 (https=)
EP (1) EP1966218B1 (https=)
JP (1) JP2009523711A (https=)
KR (1) KR20080081325A (https=)
CN (1) CN101384602A (https=)
AT (1) ATE473982T1 (https=)
AU (1) AU2006334855A1 (https=)
BR (1) BRPI0620647A2 (https=)
CA (1) CA2633698A1 (https=)
DE (2) DE102005061171A1 (https=)
ES (1) ES2347593T3 (https=)
IL (1) IL192081A0 (https=)
RU (1) RU2008129364A (https=)
WO (1) WO2007079861A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115462369A (zh) * 2022-09-29 2022-12-13 安徽省立医院(中国科学技术大学附属第一医院) 一种玻璃化冷冻外泌体保存方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007019690A1 (de) * 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027800A1 (de) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
US8163464B2 (en) 2008-08-25 2012-04-24 Du Pont Electronic Polymers L.P. Propanoates and processes for preparing the same
EP4255893A4 (en) * 2020-12-04 2025-04-23 The Johns Hopkins University COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROPATHIC PAIN

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577420A (en) 1968-01-05 1971-05-04 Pfizer Certain 4-aminofuro(2,3-d)pyrimidines
ATE266662T1 (de) 1998-07-22 2004-05-15 Daiichi Suntory Pharma Co Ltd Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU7315400A (en) 1999-09-17 2001-04-24 Daiichi Suntory Pharma Co., Ltd Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-kappab inhibitors as the active ingredient
CN100378107C (zh) 2001-05-14 2008-04-02 诺瓦提斯公司 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20030225098A1 (en) * 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
BRPI0511917A (pt) 2004-06-10 2008-01-15 Xention Discovery Ltd composto ou sais farmaceuticamente aceitáveis do mesmo, processo para preparar um composto, composição farmacêutica, método para tratar ou prevenir um distúrbio que requer a inibição do canal de potássio, e, uso de um composto
AU2005260077A1 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115462369A (zh) * 2022-09-29 2022-12-13 安徽省立医院(中国科学技术大学附属第一医院) 一种玻璃化冷冻外泌体保存方法
CN115462369B (zh) * 2022-09-29 2023-09-22 安徽省立医院(中国科学技术大学附属第一医院) 一种玻璃化冷冻外泌体保存方法

Also Published As

Publication number Publication date
DE502006007450D1 (de) 2010-08-26
IL192081A0 (en) 2008-12-29
AU2006334855A1 (en) 2007-07-19
EP1966218A1 (de) 2008-09-10
EP1966218B1 (de) 2010-07-14
US20110124665A1 (en) 2011-05-26
JP2009523711A (ja) 2009-06-25
KR20080081325A (ko) 2008-09-09
ATE473982T1 (de) 2010-07-15
BRPI0620647A2 (pt) 2011-11-16
ES2347593T3 (es) 2010-11-02
DE102005061171A1 (de) 2007-07-05
RU2008129364A (ru) 2010-01-27
CA2633698A1 (en) 2007-07-19
WO2007079861A1 (de) 2007-07-19
US8324222B2 (en) 2012-12-04

Similar Documents

Publication Publication Date Title
CN102083803A (zh) 氧代杂环取代的羧酸衍生物和它的用途
CN115298170A (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
CN1326858C (zh) 三环螺哌啶化合物
CN101094848B (zh) 有机化合物
CN101024671B (zh) 丙型肝炎病毒抑制剂
TWI494312B (zh) 二螺吡咯啶衍生物
TW202123942A (zh) Ｂｒｄ９雙官能基降解劑及其使用方法
JP2020500207A (ja) カルパインモジュレーター及びそれらの治療上の使用
CN103221408A (zh) 三嗪-*二唑类化合物
TWI758291B (zh) 經取代5,6,7,8-四氫[1,2,4]三唑并[4,3-a]吡啶-3(2h)-酮及2,5,6,7-四氫-3h-吡咯并[2,1-c][1,2,4]三唑-3-酮及其用途
CN101939317A (zh) 取代的芳基*唑和它们的应用
CN106983751A (zh) 二环取代尿嘧啶及其用途
HK1254348A1 (zh) 毒蕈碱性m2受体的正性变构调节剂
CN109790149A (zh) 苯氧基三唑类化合物
TWI770157B (zh) 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
EP4291560A1 (en) Tricyclic derivatives useful as parp7 inhibitors
CN105873919A (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
KR20200038457A (ko) 아졸로 치환된 피리딘 화합물
TW201609701A (zh) 經取代之六氫吡啶基四氫喹啉
TW202333663A (zh) Rxfp1促效劑
TWI826492B (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
JP2023027074A (ja) 複素環式プロリンアミド誘導体
CN101384603A (zh) 新的、无环取代的呋喃嘧啶衍生物及其应用
CN101384602A (zh) 用于治疗心血管疾病的新的环取代的呋喃并嘧啶衍生物及其用途
JP7076438B2 (ja) 脂肪族プロリンアミド誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130050

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMA AG

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20091127

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091127

Address after: Berlin

Applicant after: Bayer Schering Pharma AG

Address before: Germany Leverkusen

Applicant before: Bayer Healthcare AG

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1130050

Country of ref document: HK